{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:12Z","timestamp":1794047412326,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>In hemophilia A, F8 nonsense variants, and particularly those affecting the large factor VIII (FVIII) B domain that is dispensable for coagulant activity, display lower association with replacement therapy-related anti-FVIII inhibitory antibodies as retrieved from multiple international databases. Since null genetic conditions favor inhibitor development, we hypothesized that translational readthrough over premature termination codons (PTC) may contribute to immune tolerance by producing full-length proteins through the insertion of amino acid subset(s). To quantitatively evaluate the readthrough output in vitro, we developed a very sensitive luciferase-based system to detect very low full-length FVIII synthesis from a wide panel (n=45; ~60% patients with PTC) of F8 nonsense variants. PTC not associated with inhibitors displayed higher readthrough-driven expression levels than inhibitor-associated PTC, a novel observation. Particularly, higher levels were detected for B-domain variants (n=20) than for variants in other domains (n=25). Studies on plasma from six hemophilia A patients with PTC, integrated by expression of the corresponding nonsense and readthrough-deriving missense variants, consistently revealed higher FVIII levels for B-domain variants. Only one B-domain PTC (Arg814*) was found among the highly represented PTC not sporadically associated with inhibitors, but with the lowest proportion of inhibitor cases (4 out of 57). These original insights into the molecular genetics of hemophilia A, and particularly into genotype-phenotype relationships related with disease treatment, demonstrate that B-domain features favor PTC readthrough output. This provides a potential molecular mechanism contributing to differential PTC-associated inhibitor occurrence, with translational implications for a novel, experimentally based classification of F8 nonsense variants.<\/jats:p>","DOI":"10.3324\/haematol.2022.281279","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T15:11:54Z","timestamp":1659625914000},"page":"472-482","source":"Crossref","is-referenced-by-count":9,"title":["Translational readthrough at &lt;i&gt;F8&lt;\/i&gt; nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association"],"prefix":"10.3324","volume":"108","author":[{"given":"Maria Francesca","family":"Testa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Ferrarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donata","family":"Belvini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Radossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Pinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Branchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"44424","doi-asserted-by":"crossref","unstructured":"Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost. 2003; 29(1):11-22.","DOI":"10.1055\/s-2003-37935"},{"key":"44425","doi-asserted-by":"crossref","unstructured":"Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019; 104(9):1702-1709.","DOI":"10.3324\/haematol.2019.221093"},{"key":"44426","doi-asserted-by":"crossref","unstructured":"Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016; 388(10040):187-197.","DOI":"10.1016\/S0140-6736(15)01123-X"},{"key":"44427","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020; 105(3):545-553.","DOI":"10.3324\/haematol.2019.232132"},{"key":"44428","doi-asserted-by":"crossref","unstructured":"Astermark J. Overview of inhibitors. Semin Hematol. 2006; 43(2 Suppl 4):S3-7.","DOI":"10.1053\/j.seminhematol.2006.03.006"},{"key":"44429","doi-asserted-by":"crossref","unstructured":"Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol. 2011; 72(4):553-562.","DOI":"10.1111\/j.1365-2125.2010.03899.x"},{"key":"44430","doi-asserted-by":"crossref","unstructured":"Hart DP, Uzun N, Skelton S. Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. Haematologica. 2019; 104(3):599-608.","DOI":"10.3324\/haematol.2018.195669"},{"key":"44431","doi-asserted-by":"crossref","unstructured":"Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009; 35(8):723-734.","DOI":"10.1055\/s-0029-1245105"},{"key":"44432","doi-asserted-by":"crossref","unstructured":"Gouw SC, van den Berg HM, Oldenburg J. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012; 119(12):2922-2934.","DOI":"10.1182\/blood-2011-09-379453"},{"key":"44433","doi-asserted-by":"crossref","unstructured":"Shinozawa K, Yada K, Kojima T. Spectrum of F8 genotype and genetic impact on inhibitor development in patients with hemophilia A from multicenter cohort studies (J-HIS) in Japan. Thromb Haemost. 2021; 121(5):603-615.","DOI":"10.1055\/s-0040-1721385"},{"key":"44434","doi-asserted-by":"crossref","unstructured":"Krawczak M, Ball EV, Fenton I. Human gene mutation database-a biomedical information and research resource. Hum Mutat. 2000; 15(1):45-51.","DOI":"10.1002\/(SICI)1098-1004(200001)15:1<45::AID-HUMU10>3.0.CO;2-T"},{"key":"44435","doi-asserted-by":"crossref","unstructured":"Mort M, Ivanov D, Cooper DN, Chuzhanova NA. A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat. 2008; 29(8):1037-1047.","DOI":"10.1002\/humu.20763"},{"key":"44436","doi-asserted-by":"crossref","unstructured":"Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell. 2001; 107(4):411-414.","DOI":"10.1016\/S0092-8674(01)00583-9"},{"key":"44437","doi-asserted-by":"crossref","unstructured":"Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet. 2006; 14(10):1074-1081.","DOI":"10.1038\/sj.ejhg.5201649"},{"key":"44438","doi-asserted-by":"crossref","unstructured":"Spena S, Garagiola I, Cannav\u00f2 A. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost. 2018; 16(4):778-790.","DOI":"10.1111\/jth.13961"},{"key":"44439","doi-asserted-by":"crossref","unstructured":"Bonetti B, Fu L, Moon J, Bedwell DM. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol. 1995; 251(3):334-345.","DOI":"10.1006\/jmbi.1995.0438"},{"key":"44440","doi-asserted-by":"crossref","unstructured":"Blanchet S, Cornu D, Argentini M, Namy O. New insights into the incorporation of natural suppressor tRNAs at stop codons in Saccharomyces cerevisiae. Nucleic Acids Res. 2014; 42(15):10061-10072.","DOI":"10.1093\/nar\/gku663"},{"key":"44441","doi-asserted-by":"crossref","unstructured":"Blanchet S, Cornu D, Hatin I. Deciphering the reading of the genetic code by near-cognate tRNA. Proc Natl Acad Sci U S A. 2018; 115(12):3018-3023.","DOI":"10.1073\/pnas.1715578115"},{"key":"44442","doi-asserted-by":"crossref","unstructured":"Rospert S, Rakwalska M, Dubaqui\u00e9 Y. Polypeptide chain termination and stop codon readthrough on eukaryotic ribosomes. Rev Physiol Biochem Pharmacol. 2005; 155:1-30.","DOI":"10.1007\/3-540-28217-3_1"},{"key":"44443","doi-asserted-by":"crossref","unstructured":"Pacho F, Zambruno G, Calabresi V, Kiritsi D, Schneider H. Efficiency of translation termination in humans is highly dependent upon nucleotides in the neighbourhood of a (premature) termination codon. J Med Genet. 2011; 48(9):640-644.","DOI":"10.1136\/jmg.2011.089615"},{"key":"44444","doi-asserted-by":"crossref","unstructured":"Pinotti M, Caruso P, Canella A. Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations. Hum Mutat. 2012; 33(9):1373-1376.","DOI":"10.1002\/humu.22120"},{"key":"44445","doi-asserted-by":"crossref","unstructured":"Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA. 2000; 6(7):1044-1055.","DOI":"10.1017\/S1355838200000716"},{"key":"44446","doi-asserted-by":"crossref","unstructured":"Branchini A, Ferrarese M, Lombardi S. Differential functional readthrough over homozygous nonsense mutations contributes to the bleeding phenotype in coagulation factor VII deficiency. J Thromb Haemost. 2016; 14(10):1994-2000.","DOI":"10.1111\/jth.13443"},{"key":"44447","doi-asserted-by":"crossref","unstructured":"Branchini A, Ferrarese M, Campioni M. Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations. Blood. 2017; 129(16):2303-2307.","DOI":"10.1182\/blood-2016-09-738641"},{"key":"44448","doi-asserted-by":"crossref","unstructured":"Lombardi S, Ferrarese M, Marchi S. Translational readthrough of GLA nonsense mutations suggests dominantnegative effects exerted by the interaction of wild-type and missense variants. RNA Biol. 2020; 17(2):254-263.","DOI":"10.1080\/15476286.2019.1676115"},{"key":"44449","doi-asserted-by":"crossref","unstructured":"Ferrarese M, Baroni M, Della Valle P. Missense changes in the catalytic domain of coagulation factor X account for minimal function preventing a perinatal lethal condition. Haemophilia. 2019; 25(4):685-692.","DOI":"10.1111\/hae.13761"},{"key":"44450","doi-asserted-by":"crossref","unstructured":"Martorell L, Cortina V, Parra R, Barquinero J, Vidal F. Variable readthrough responsiveness of nonsense mutations in hemophilia A. Haematologica. 2020; 105(2):508-518.","DOI":"10.3324\/haematol.2018.212118"},{"key":"44451","doi-asserted-by":"crossref","unstructured":"Ferrarese M, Testa MF, Balestra D. Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B. Hum Mutat. 2018; 39(5):702-708.","DOI":"10.1002\/humu.23404"},{"key":"44452","doi-asserted-by":"crossref","unstructured":"Shen BW, Spiegel PC, Chang C-H. The tertiary structure and domain organization of coagulation factor VIII. Blood. 2008; 111(3):1240-1247.","DOI":"10.1182\/blood-2007-08-109918"},{"key":"44453","doi-asserted-by":"crossref","unstructured":"Camire RM, Bos MHA. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost. 2009; 7(12):1951-1961.","DOI":"10.1111\/j.1538-7836.2009.03622.x"},{"key":"44454","doi-asserted-by":"crossref","unstructured":"Stennicke HR, Kjalke M, Karpf DM. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013; 121(11):2108-2116.","DOI":"10.1182\/blood-2012-01-407494"},{"key":"44455","doi-asserted-by":"crossref","unstructured":"Rosen S, Tiefenbacher S, Robinson M. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy. Blood. 2020; 136(22):2524-2534.","DOI":"10.1182\/blood.2020005683"},{"key":"44456","doi-asserted-by":"crossref","unstructured":"Seth Chhabra E, Liu T, Kulman J. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020; 135(17):1484-1496.","DOI":"10.1182\/blood.2019001292"},{"key":"44457","doi-asserted-by":"crossref","unstructured":"Ogata K, Selvaraj SR, Miao HZ, Pipe SW. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping. J Thromb Haemost. 2011; 9(6):1183-1190.","DOI":"10.1111\/j.1538-7836.2011.04268.x"},{"key":"44458","doi-asserted-by":"crossref","unstructured":"Jourdy Y, Nougier C, Roualdes O. Characterization of five associations of F8 missense mutations containing FVIII B domain mutations. Haemophilia. 2016; 22(4):583-589.","DOI":"10.1111\/hae.12906"},{"key":"44459","doi-asserted-by":"crossref","unstructured":"den Dunnen JT, Dalgleish R, Maglott DR. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016; 37(6):564-569.","DOI":"10.1002\/humu.22981"},{"key":"44460","doi-asserted-by":"crossref","unstructured":"McVey JH, Rallapalli PM, Kemball-Cook G. The European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation Factor Variant Databases: important resources for haemostasis clinicians and researchers. Haemophilia. 2020; 26(2):306-313.","DOI":"10.1111\/hae.13947"},{"key":"44461","doi-asserted-by":"crossref","unstructured":"Payne AB, Miller CH, Kelly FM, Michael Soucie J, Craig Hooper W. The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource. Hum Mutat. 2013; 34(2):E2382-2391.","DOI":"10.1002\/humu.22247"},{"key":"44462","doi-asserted-by":"crossref","unstructured":"Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015; 31(16):2745-2747.","DOI":"10.1093\/bioinformatics\/btv195"},{"key":"44463","doi-asserted-by":"crossref","unstructured":"Sim N-L, Kumar P, Hu J. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012; 40(Web Server issue):W452-457.","DOI":"10.1093\/nar\/gks539"},{"key":"44464","doi-asserted-by":"crossref","unstructured":"Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013.","DOI":"10.1002\/0471142905.hg0720s76"},{"key":"44465","doi-asserted-by":"crossref","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016; 99(4):877-885.","DOI":"10.1016\/j.ajhg.2016.08.016"},{"key":"44466","doi-asserted-by":"crossref","unstructured":"Bern M, Nilsen J, Ferrarese M. An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics. Sci Transl Med. 2020; 12(565):eabb0580.","DOI":"10.1126\/scitranslmed.abb0580"},{"key":"44467","doi-asserted-by":"crossref","unstructured":"Lombardi S, Aaen KH, Nilsen J. Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity. Br J Haematol. 2021; 194(2):453-462.","DOI":"10.1111\/bjh.17559"},{"key":"44468","doi-asserted-by":"crossref","unstructured":"Pattinson JK, Millar DS, McVey JH. The molecular genetic analysis of hemophilia A: a directed search strategy for the detection of point mutations in the human factor VIII gene. Blood. 1990; 76(11):2242-2248.","DOI":"10.1182\/blood.V76.11.2242.2242"},{"key":"44469","doi-asserted-by":"crossref","unstructured":"El-Maarri O, Olek A, Balaban B. Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution. Am J Hum Genet. 1998; 63(4):1001-1008.","DOI":"10.1086\/302065"},{"key":"44470","doi-asserted-by":"crossref","unstructured":"Jopling CL. Stop that nonsense!. Elife. 2014; 3:e04300.","DOI":"10.7554\/eLife.04300"},{"key":"44471","doi-asserted-by":"crossref","unstructured":"Saenko EL, Ananyeva NM, Kouiavskaia DV. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action. Haemophilia. 2002; 8(1):1-11.","DOI":"10.1046\/j.1365-2516.2002.00579.x"},{"key":"44472","doi-asserted-by":"crossref","unstructured":"Walter JD, Werther RA, Brison CM. Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. Blood. 2013; 122(26):4270-4278.","DOI":"10.1182\/blood-2013-08-519124"},{"key":"44473","doi-asserted-by":"crossref","unstructured":"Gangadharan B, Ing M, Delignat S. The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells. Haematologica. 2017; 102(2):271-281.","DOI":"10.3324\/haematol.2016.148502"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281279\/74737","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281279\/75255","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10734\/74737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:09Z","timestamp":1794045729000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281279","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}